NO974964L - Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse - Google Patents

Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse

Info

Publication number
NO974964L
NO974964L NO974964A NO974964A NO974964L NO 974964 L NO974964 L NO 974964L NO 974964 A NO974964 A NO 974964A NO 974964 A NO974964 A NO 974964A NO 974964 L NO974964 L NO 974964L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
applications
genetic sequences
useful
Prior art date
Application number
NO974964A
Other languages
English (en)
Norwegian (no)
Other versions
NO974964D0 (no
Inventor
Peter H St George-Hyslop
Paul E Fraser
Johanna M Rommens
Original Assignee
Hsc Res Dev Lp
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,048 external-priority patent/US6531586B1/en
Priority claimed from US08/496,841 external-priority patent/US6210919B1/en
Application filed by Hsc Res Dev Lp, Univ Toronto filed Critical Hsc Res Dev Lp
Publication of NO974964D0 publication Critical patent/NO974964D0/no
Publication of NO974964L publication Critical patent/NO974964L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/63—Genetically modified worms
    • A01K67/64—Genetically modified nematodes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/703—Worms, e.g. Caenorhabdities elegans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
NO974964A 1995-04-28 1997-10-27 Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse NO974964L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/431,048 US6531586B1 (en) 1995-04-28 1995-04-28 Genetic sequences related to Alzheimer's Disease
US08/496,841 US6210919B1 (en) 1995-04-28 1995-06-28 Genetic sequences and proteins related to alzheimer's disease
US50935995A 1995-07-31 1995-07-31
PCT/CA1996/000263 WO1996034099A2 (en) 1995-04-28 1996-04-29 Genetic sequences and proteins related to alzheimer's disease, and uses therefor

Publications (2)

Publication Number Publication Date
NO974964D0 NO974964D0 (no) 1997-10-27
NO974964L true NO974964L (no) 1997-12-29

Family

ID=27411707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974964A NO974964L (no) 1995-04-28 1997-10-27 Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse

Country Status (19)

Country Link
US (9) US5986054A (de)
EP (2) EP2000479A1 (de)
JP (3) JP4504463B2 (de)
KR (1) KR19990008181A (de)
AT (1) ATE405645T1 (de)
AU (1) AU716307B2 (de)
BR (1) BR9608140A (de)
CA (1) CA2219214A1 (de)
CZ (1) CZ339097A3 (de)
DE (1) DE69637649D1 (de)
DK (1) DK0826042T3 (de)
ES (1) ES2314979T3 (de)
HU (1) HUP9801639A3 (de)
MX (1) MX9708270A (de)
NO (1) NO974964L (de)
NZ (2) NZ305822A (de)
PL (1) PL185549B1 (de)
SK (1) SK145397A3 (de)
WO (1) WO1996034099A2 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
DE69635207T2 (de) * 1995-07-07 2006-06-22 Darwin Molecular Corp. Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
WO1997003999A1 (en) * 1995-07-18 1997-02-06 Washington University School Of Medicine Mutant s182 genes
US5985564A (en) * 1995-08-16 1999-11-16 President And Fellows Of Harvard College Assay for identifying agents that inhibit chromosome non-disjunction
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
CA2233297A1 (en) * 1995-09-27 1997-04-03 Iva Greenwald Identification of sel-12 and uses thereof
ZA968898B (en) * 1995-10-25 1998-03-30 Washington University Of Medic Method for elucidation and detection of polymorphisms, splice variants and proximal coding mutations using intronic sequences of the mutations Alzheimer's S182 gene.
JPH10327897A (ja) * 1996-01-19 1998-12-15 Washington Univ プレセニリン−１遺伝子の配列を用いる疾患の診断および予後診断
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
WO1997038133A1 (en) * 1996-04-04 1997-10-16 University Of South Florida Variant presenilin-2 genes
WO1997046678A1 (en) * 1996-06-06 1997-12-11 Bayer Corporation Nucleic acids and polypeptides related to presenilin
EP0811695A3 (de) * 1996-06-06 1998-07-29 Washington University Mutierte S182(PS-1) Gene
EP0814157A3 (de) * 1996-06-18 1998-01-07 Smithkline Beecham Corporation Diagnostischer Masker für Varianten von Presenilin Genen, verbunden mit alzheimerischen Krankheit und familiären erwachsenen Einsetzens alzheimerischen Krankheit
JP2000516087A (ja) * 1996-07-05 2000-12-05 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
WO1998025142A1 (en) 1996-12-02 1998-06-11 The Brigham And Women's Hospital, Inc. Alarm related peptides and nucleic acids and diagnosis using them
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US6376239B1 (en) * 1997-04-04 2002-04-23 Elegene Gmbh DNA molecules comprising a promoter capable of conferring expression of a heterologous DNA sequence
WO1998047917A2 (en) * 1997-04-24 1998-10-29 The General Hospital Corporation A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
CA2290039A1 (en) * 1997-05-14 1998-11-19 Merck & Co., Inc. Transgenic animal expressing non-native wild-type and familial alzheimer's disease mutant presenilin 1 protein on native presenilin 1 null background
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
ATE352558T1 (de) * 1997-08-14 2007-02-15 Pasteur Institut Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
US6284944B1 (en) * 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
FR2768346B1 (fr) 1997-09-15 2002-04-19 Fond Jean Dausset Ceph Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
JP2001521043A (ja) * 1997-10-24 2001-11-06 アバンテイス・フアルマ・エス・アー プレセニリンとβ−アミロイドペプチドまたはその前駆体との相互作用を阻害し得るペプチド
FR2770217B1 (fr) * 1997-10-24 2001-12-07 Rhone Poulenc Rorer Sa Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
EP1044605B1 (de) * 1998-01-08 2007-04-25 Daiichi Pharmaceutical Co., Ltd. Genmutierte tiere
WO1999035501A1 (en) * 1998-01-09 1999-07-15 The Governing Council Of The University Of Toronto Presenilin protein interactions
EP1849477A1 (de) * 1998-02-25 2007-10-31 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Mitteln zur Verbesserung der Hautpenetration und schrankenbrechenden Mitteln zur Verbesserung der transkutanen Immunantwort
DE69940906D1 (de) * 1998-05-21 2009-07-02 Mitsubishi Tanabe Pharma Corp Verfahren zur untersuchung von krankheiten des zentralen nervensystems und verfahren zum aufsuchen von arzneimitteln
AR020329A1 (es) * 1998-07-09 2002-05-08 Boehringer Ingelheim Pharma UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
JP2002520055A (ja) * 1998-07-16 2002-07-09 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトプレセニリン関連タンパク質
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6723557B1 (en) 1999-01-06 2004-04-20 California Institute Of Technology Caenorhabditis elegans LOV-1 gene
US6783982B1 (en) 1999-02-12 2004-08-31 The Governing Council Of The University Of Toronto Proteins related to neuronal regeneration and uses thereof
US6812337B1 (en) * 1999-04-01 2004-11-02 The Governing Council Of The University Of Toronto Presenilin associated membrane protein and uses thereof
WO2000059297A2 (en) * 1999-04-06 2000-10-12 Harrington Arthritis Research Center Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
AU6265600A (en) * 1999-06-22 2001-01-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for detection of early-onset alzheimer's disease
EP1194449B1 (de) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
US20020049303A1 (en) * 1999-06-28 2002-04-25 Tang Jordan J. N. Catalytically active recombinant memapsin and methods of use thereof
FR2798821B1 (fr) * 1999-09-27 2001-10-26 Aventis Pharma Sa Animal transgenique exprimant une forme multi-mutee de la preseniline 1
AU2001227960A1 (en) * 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
IL151828A0 (en) 2000-04-03 2003-04-10 Bristol Myers Squibb Pharma Co Proteins having gamma-secretase activity and methods for isolating the same and methods detecting said activity
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US7371920B2 (en) 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
AU2001273661A1 (en) * 2000-06-30 2002-01-14 Duke University Methods of screening for alzheimer's disease
DE10032709A1 (de) * 2000-07-07 2002-01-24 Boehringer Ingelheim Pharma Aspartyl-Protease
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
JP2002142765A (ja) * 2000-07-14 2002-05-21 Tosoh Corp 新規ゲノム解析法
WO2002014546A1 (en) * 2000-08-16 2002-02-21 Markus Fritzsche Use of microbial dna sequences for the identification of human diseases
AU2001287448A1 (en) * 2000-09-01 2002-03-13 The Governing Council Of The University Of Toronto Proteins related to schizophrenia and uses thereof
US6900367B2 (en) * 2000-09-29 2005-05-31 Novartis Transgenic Drosophila melanogaster expressing a β42 in the eye
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20030073608A1 (en) * 2001-04-10 2003-04-17 Woolf Nancy J. Process for treating disease
GB2375771A (en) * 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
JP2003012548A (ja) * 2001-06-27 2003-01-15 Japan Science & Technology Corp 医薬組成物
EP2354793B1 (de) 2001-08-14 2016-06-22 Sentigen Biosciences, Inc. Nukleinsäuren und Proteine von Insekten OR83B-Duftrezeptorgenen und Verwendungen davon
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
EP1448218A4 (de) * 2001-10-23 2009-01-14 Oklahoma Med Res Found Beta-secretase-hemmer und anwendungsverfahren
EP1456668B1 (de) * 2001-12-05 2007-05-02 Sense Proteomic Limited Protein arrays für allelvarianten und deren verwendung
AU2002359781A1 (en) * 2001-12-20 2003-07-09 The Regents Of The University Of California Triple transgenic mouse model of alzheimer's disease
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
WO2004005921A1 (en) * 2002-07-05 2004-01-15 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
US20060183117A1 (en) * 2002-07-08 2006-08-17 Pericak-Vance Margaret A Screening for alzheimer's disease
US20040076606A1 (en) * 2002-09-14 2004-04-22 Ming-Shi Chang Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
WO2005075684A2 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier
US20050170392A1 (en) * 2004-01-30 2005-08-04 Xenoport, Inc. OAT3 transporters expressed in blood brain barrier cells
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7833725B2 (en) * 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
US7704696B2 (en) * 2005-07-29 2010-04-27 Xenoport, Inc. Screening of compounds for OCTN2 transporter activity
US7670782B2 (en) * 2005-07-29 2010-03-02 Xenoport, Inc. Screening of compounds for CAT1 transporter activity
US7691584B2 (en) * 2005-07-29 2010-04-06 Xenoport, Inc. Screening of compounds for OCT3 transporter activity
US7704695B2 (en) * 2005-07-29 2010-04-27 Xenoport, Inc. Screening of compounds for BGT1 transporter activity
WO2007016159A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Gat2 transporters expressed in blood brain barrier cells
WO2007021886A2 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
US8852585B2 (en) 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
WO2007092861A2 (en) * 2006-02-06 2007-08-16 Elan Pharmaceuticals, Inc. Inhibitors specific of presenilin-1 and their uses
WO2007123680A2 (en) 2006-03-31 2007-11-01 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US7771741B2 (en) * 2006-05-01 2010-08-10 Warsaw Orthopedic, Inc Demineralized bone matrix devices
EP2024503A2 (de) * 2006-05-01 2009-02-18 Aarhus Universitet Tiermodell und verfahren zur erzeugung eines tiermodells
EP2134846B1 (de) * 2007-03-07 2018-08-08 Aarhus Universitet Transgenes schwein als modell für morbus alzheimer
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9068006B2 (en) 2010-08-25 2015-06-30 President And Fellows Of Harvard College Glycated CD59 peptides, their preparation, and uses thereof
EP2857499A1 (de) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Manipulierte Nukleinsäuren und Verfahren zur Verwendung davon
US20140193341A1 (en) * 2011-01-19 2014-07-10 Asa Abeliovich Human induced neuronal cells
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012178183A1 (en) * 2011-06-24 2012-12-27 Board Of Regents, The University Of Texas System Human age-related neurodegenerative nematode model and methods
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
EP2791159A4 (de) * 2011-12-14 2015-10-14 Moderna Therapeutics Inc Modifizierte nucleinsäuren und akutbehandlungsverwendungen davon
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2530141B1 (es) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3347486A4 (de) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York Reduktion von er-mam-lokalisierten app-c99 und verfahren zur behandlung der alzheimer-krankheit
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
ES2817910T3 (es) * 2017-08-04 2021-04-08 Alzheimur 2012 S L Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
AU2019272848A1 (en) * 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CA3141712A1 (en) * 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR102584857B1 (ko) * 2020-09-23 2023-10-06 재단법인대구경북과학기술원 알츠하이머 동물모델 및 이의 용도
KR20230009140A (ko) * 2021-07-08 2023-01-17 주식회사 엠케이바이오텍 Human mutant Presenilin-1 발현 인지장애 모델 개의 생산

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690893A (en) * 1985-05-03 1987-09-01 Dnax Research Institute Of Molecular And Cellular Biology, Inc. Hybridoma cell lines producing monoclonal antibodies which specifically bind to mouse interleukin-2
JPH0779702B2 (ja) * 1986-11-17 1995-08-30 サイオス ノバ インコーポレイテッド 組換えアルツハイマーアミロイドタンパク
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
JPH05199896A (ja) * 1990-10-29 1993-08-10 Shinetsu Bio Inc モノクローナル抗体含有試薬
JP3293622B2 (ja) 1991-03-15 2002-06-17 エイチエスシー リサーチ アンド ディヴェロップメント リミテッド パートナーシップ 形質転換された魚類の製造用の遺伝子構築体
US5297562A (en) * 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
NZ242955A (en) * 1991-06-13 1995-01-27 Ici Plc Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code
IL105793A0 (en) * 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
WO1994000569A1 (en) * 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5668006A (en) * 1992-07-17 1997-09-16 American Cyanamid Company Somatostatin receptors
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
WO1994023049A2 (en) * 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6998467B1 (en) * 1995-04-28 2006-02-14 The Hospital For Sick Children Antibody specific for presenilin 1 and method of use thereof
US6210919B1 (en) * 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6531586B1 (en) * 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
DE69635207T2 (de) 1995-07-07 2006-06-22 Darwin Molecular Corp. Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
WO1997003086A1 (en) * 1995-07-13 1997-01-30 University Of South Florida Early onset alzheimer's disease gene and gene products
WO1997003999A1 (en) * 1995-07-18 1997-02-06 Washington University School Of Medicine Mutant s182 genes
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor

Also Published As

Publication number Publication date
ATE405645T1 (de) 2008-09-15
HUP9801639A3 (en) 2001-01-29
EP0826042A2 (de) 1998-03-04
NZ305822A (en) 2000-08-25
US7507798B2 (en) 2009-03-24
US7846679B2 (en) 2010-12-07
NZ335945A (en) 2000-09-29
JP4504463B2 (ja) 2010-07-14
CA2219214A1 (en) 1996-10-31
DK0826042T3 (da) 2008-11-24
DE69637649D1 (de) 2008-10-02
BR9608140A (pt) 1999-12-07
EP0826042B1 (de) 2008-08-20
EP2000479A1 (de) 2008-12-10
US20050214837A1 (en) 2005-09-29
CZ339097A3 (cs) 1998-02-18
ES2314979T3 (es) 2009-03-16
AU5394096A (en) 1996-11-18
US7838247B2 (en) 2010-11-23
US6117978A (en) 2000-09-12
US20080286813A1 (en) 2008-11-20
US5840540A (en) 1998-11-24
JP2007297407A (ja) 2007-11-15
SK145397A3 (en) 1998-09-09
PL185549B1 (pl) 2003-05-30
US20090191650A1 (en) 2009-07-30
US6395960B1 (en) 2002-05-28
PL323109A1 (en) 1998-03-16
US6485911B1 (en) 2002-11-26
HUP9801639A2 (hu) 1998-10-28
JP2013107890A (ja) 2013-06-06
KR19990008181A (ko) 1999-01-25
US6194153B1 (en) 2001-02-27
JPH11504214A (ja) 1999-04-20
MX9708270A (es) 1998-06-28
US5986054A (en) 1999-11-16
WO1996034099A2 (en) 1996-10-31
WO1996034099A3 (en) 1996-12-05
NO974964D0 (no) 1997-10-27
AU716307B2 (en) 2000-02-24
JP5053746B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
NO974964D0 (no) Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse
Gehrke et al. Deep conservation of wrist and digit enhancers in fish
Li et al. A systematic approach to identify functional motifs within vertebrate developmental enhancers
WO2004007722A3 (en) Transgenic animal expressing alzheimer’s tau protein
EP1319408A4 (de) Arzneimittel für herzversagen
Kimura-Yoshida et al. Crucial roles of Foxa2 in mouse anterior–posterior axis polarization via regulation of anterior visceral endoderm-specific genes
WO1998001549A3 (en) Genetic sequences and proteins related to alzheimer's disease, and uses therefor
Zhou et al. Comparative genomics and epigenomics of transcriptional regulation
Negrón-Piñeiro et al. Cis-regulatory interfaces reveal the molecular mechanisms underlying the notochord gene regulatory network of Ciona
Hendriks et al. Life-cycle differentiation in Trypanosoma brucei: molecules and mutants
Wunderlich et al. Modeling transcriptional networks in Drosophila development at multiple scales
EA199900184A1 (ru) Протеинкиназы и их применение
NO985280D0 (no) Anvendelse av en mutasjon i genet for human G-protein 3 subenhet for diagnostisering av sykdommer
Egervari Chromatin accessibility in neuropsychiatric disorders
Fu et al. Extended cleavage specificity of sheep mast cell protease-2: A classical chymase with preference to aromatic P1 substrate residues
ATE393229T1 (de) Tau-opathy modell
WO2002101232A3 (en) Bace interacting proteins
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
WO2004042363A3 (en) In vivo imaging of e2f-regulated bioluminescent proteins
WO2003044170A3 (en) Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
Roca et al. MEC-2/Stomatin is required for aversive behaviour but dispensable for prey detection in the predatory nematode Pristionchus pacificus
KR20190103711A (ko) Gng8 유전자를 녹아웃시킨 동물모델 및 이의 용도
ATE343632T1 (de) Mutiertes nurr1 gen
Marco de Lucas et al. White Paper 3: Genome and Epigenetics
Pelletier et al. Multiple cis-regulatory modules ensure robust tup/islet1 function in dorsal muscle identity specification

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application